Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 13,900 shares, an increase of 18.8% from the November 15th total of 11,700 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 48,600 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Tuesday, November 19th.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS stock traded up $0.09 during mid-day trading on Friday, reaching $0.91. 20,486 shares of the company’s stock traded hands, compared to its average volume of 28,605. Barinthus Biotherapeutics has a 12 month low of $0.80 and a 12 month high of $4.16. The firm has a market capitalization of $36.71 million, a PE ratio of -0.61 and a beta of -0.73. The firm has a 50 day moving average price of $1.17 and a two-hundred day moving average price of $1.35.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter last year, the business earned ($0.37) EPS. As a group, equities analysts expect that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Alphabet Inc. bought a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,513,644 shares of the company’s stock, valued at approximately $2,119,000. Barinthus Biotherapeutics comprises about 0.1% of Alphabet Inc.’s holdings, making the stock its 29th largest position. Alphabet Inc. owned approximately 3.88% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 25.20% of the stock is currently owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.